Orphazyme A/S
CSE:ORPHA

Watchlist Manager
Orphazyme A/S Logo
Orphazyme A/S
CSE:ORPHA
Watchlist
Price: 850 DKK 1.19% Market Closed
Market Cap: 34m DKK

Relative Value

There is not enough data to reliably calculate the relative value of ORPHA.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ORPHA Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
87
Median 3Y
0
Median 5Y
0
Industry
7.8
Forward
0
vs History
vs Industry
12
Median 3Y
-2
Median 5Y
-1.8
Industry
24.1
Forward
15
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-2.3
Industry
21.8
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-2.3
Industry
23.8
vs History
58
vs Industry
40
Median 3Y
2.1
Median 5Y
2.2
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8
Forward
0
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
vs History
vs Industry
31
Median 3Y
-1.3
Median 5Y
-1.3
Industry
6.3
Forward
0
vs History
vs Industry
30
Median 3Y
-1.3
Median 5Y
-1.3
Industry
6.7
Forward
0
vs History
vs Industry
32
Median 3Y
-2.1
Median 5Y
-1.6
Industry
7.9
vs History
vs Industry
29
Median 3Y
-2.1
Median 5Y
-1.6
Industry
6.3
vs History
42
vs Industry
20
Median 3Y
9.5
Median 5Y
9.5
Industry
5.5

Multiples Across Competitors

ORPHA Competitors Multiples
Orphazyme A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Orphazyme A/S
CSE:ORPHA
34m DKK 0 -3 -1.3 -1.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 837 682.7 -160 825.5 -195 293.4 -193 064.9
US
Abbvie Inc
NYSE:ABBV
400.9B USD 6.7 170.7 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
176.1B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
154.4B USD 5.3 19 12.8 12.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 9.9 31.5 23.1 24.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 082 -531.3 -578.5 -563.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.9B USD 5.7 17.7 16.8 19.1
AU
CSL Ltd
ASX:CSL
84.8B AUD 3.6 18.7 12.6 15.7
NL
argenx SE
XBRU:ARGX
45B EUR 14.6 34.4 59.4 61.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD 16.4 1 210.8 159.1 192.9
P/S Multiple
Revenue Growth P/S to Growth
DK
Orphazyme A/S
CSE:ORPHA
Average P/S: 3 383 983.2
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 837 682.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 082
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
14.6
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
P/E Multiple
Earnings Growth PEG
DK
Orphazyme A/S
CSE:ORPHA
Average P/E: 191
Negative Multiple: -3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 825.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
9%
2
AU
CSL Ltd
ASX:CSL
18.7
11%
1.7
NL
argenx SE
XBRU:ARGX
34.4
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 210.8
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Orphazyme A/S
CSE:ORPHA
Average EV/EBITDA: 39.8
Negative Multiple: -1.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 293.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
NL
argenx SE
XBRU:ARGX
59.4
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
159.1
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Orphazyme A/S
CSE:ORPHA
Average EV/EBIT: 45.9
Negative Multiple: -1.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 064.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.1
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
NL
argenx SE
XBRU:ARGX
61.1
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
192.9
N/A N/A